1. 4B.01: CONTRASTING INFLUENCES OF RENAL FUNCTION ON BLOOD PRESSURE AND HBA1C REDUCTIONS WITH EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION. (June 2015) Authors: Cherney, D.; Cooper, M.; Tikkanen, I.; Crowe, S.; Johansen, O.E.; Lund, S.S.; Woerle, H.J.; Broedl, U.C.; Hach, T. Journal: Journal of hypertension Issue: Volume 33(2015)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 4B.02: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES BLOOD PRESSURE AND MARKERS OF ARTERIAL STIFFNESS AND VASCULAR RESISTANCE IN TYPE 2 DIABETES. (June 2015) Authors: Chilton, R.; Tikkanen, I.; Cannon, C.P.; Crowe, S.; Hach, T.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E. Journal: Journal of hypertension Issue: Volume 33(2015)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 4B.03: EMPAGLIFLOZIN REDUCES SYSTOLIC BLOOD PRESSURE IN DIPPER AND NON-DIPPER PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION. (June 2015) Authors: Chilton, R.; Tikkanen, I.; Crowe, S.; Johansen, O.E.; Broedl, U.C.; Woerle, H.J.; Hach, T. Journal: Journal of hypertension Issue: Volume 33(2015)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. [OP.7D.07] INFLUENCE OF RENAL SYMPATHETIC DENERVATION ON BLOOD PRESSURE VARIABILITY: EXPERIENCE AT 11 EUROPEAN EXPERT CENTERS. (September 2016) Authors: Persu, A.; Gordin, D.; Jacobs, L.; Thijs, L.; Bots, M.L.; Miroslawska, A.; Spaak, J.; Rosa, J.; De Jong, M.; Berra, E.; Elmula, F.E. Fadl; Wuerzner, G.; Taylor, A.; Olszanecka, A.; Czarnecka, D.; Mark, P.B.; Burnier, M.; Renkin, J.; Kjeldsen, S.E.; Widimsky, J. Journal: Journal of hypertension Issue: Volume 34:(2016) Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. [PP.10.04] BLOOD PRESSURE RESPONSE TO RENAL DENERVATION ACCORDING TO THE PRESENCE OR ABSENCE OF RENAL ACCESSORY ARTERIES. (September 2016) Authors: Jacobs, L.; Persu, A.; Hammer, F.; Renkin, J.; Widimsky, J.; Rosa, J.; Kjeldsen, S.E.; Elmula, F.E. Fadl; Elvan, A.; Czarnecka, D.; Olszanecka, A.; Gordin, D.; Tikkanen, I.; Staessen, J.A. Journal: Journal of hypertension Issue: Volume 34:(2016) Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. [PP.13.09] THE EFFECTS OF BAROREFLEX ACTIVATION THERAPY ON BLOOD PRESSURE AND SYMPATHETIC FUNCTION IN PATIENTS WITH REFRACTORY HYPERTENSION – THE RATIONALE AND DESIGN OF THE NORDIC BAT STUDY. (September 2016) Authors: Gordin, D.; Elmula, F.E. Fadl; Andersson, B.; Gottsäter, A.; Kahan, T.; Viigimaa, M.; Kjeldsen, S.E.; Christensen, K. Lodberg; Olsen, M.H.; Tikkanen, I. Journal: Journal of hypertension Issue: Volume 34:(2016) Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Issue 12 (9th October 2015) Authors: Chilton, R.; Tikkanen, I.; Cannon, C. P.; Crowe, S.; Woerle, H. J.; Broedl, U. C.; Johansen, O. E. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 12(2015:Dec.) Page Start: 1180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. ESH-ENDORSED EUROPEAN/INTERNATIONAL FIBROMUSCULAR DYSPLASIA REGISTRY: RESULTS OF THE FIRST 609 PATIENTS. (June 2018) Authors: Di Monaco, S.; Azizi, M.; Aparicio, L.S.; Witowicz, H.; Bruno, R.M.; Delmotte, P.; Tikkanen, I.; Seinturier, C.; Kroon, A.A.; Van Der Niepen, P.; Toubiana, L.; Januszewicz, A.; Plouin, P.-F.; Persu, A. Journal: Journal of hypertension Issue: Volume 36(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Tankyrase inhibition attenuates cardiac dilatation and dysfunction in ischemic heart failure. (August 2022) Authors: Wang, H.; Segersvärd, H.; Siren, J.; Perttunen, S.; Immonen, K.; Kosonen, R.; Chen, Y.-C.; Tolva, J.M.; Laivuori, M.; Mäyränpää, M.I.; Kovanen, P.T.; Sinisalo, J.; Laine, M.; Tikkanen, I.; Lakkisto, P. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗